12:00 AM
 | 
Aug 13, 2012
 |  BC Week In Review  |  Company News  |  Deals

Amylin, Bristol-Myers deal

Bristol-Myers completed its acquisition of Amylin for $31 per share. The $7 billion deal includes $5.3 billion for Amylin stock and $1.7 billion to pay off the biotech's debt and a contractual obligation. Bristol-Myers will fold Amylin's diabetes portfolio into its existing diabetes deal with AstraZeneca plc (LSE:AZN; NYSE:AZN,...

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >